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Abstract 6 
The additive Calsporin® is a preparation containing viable spores of a single strain of Bacillus subtilis. 7 
The product was previously assessed by the European Food Safety Authority and is currently 8 
authorised for use in chickens for fattening, weaned piglets, chickens reared for laying, turkeys, minor 9 
avian species and other ornamental and game birds. The present application is for an extension of use 10 
in feed for laying hens and minor avian species for laying and for game, sporting and ornamental 11 
birds for laying. No evidence of toxigenic potential or resistance to antibiotics of human and veterinary 12 
importance was found, as judged by the current guidelines. Thus the conclusion reached in previous 13 
opinions that this strain of B. subtilis is presumed safe for target animals, consumers and the 14 
environment is still considered valid. This conclusion automatically covers the use of the additive in 15 
feed for laying hens and for all avian species for laying. Use of the additive in feed for laying hens and 16 
for all avian species for laying will not introduce hazards for users not already considered. In the three 17 
trials conducted with laying hens the amount of feed needed to produce a unit of egg mass was 18 
significantly reduced when Calsporin® was included at the minimum recommended dose of 3 × 108 19 
colony-forming units per kilogram of feed. While the Panel notes that one of the studies involved 20 
layers in the second half of production rather than from the onset of laying, the positive outcome is 21 
taken to indicate a potential for efficacy over the entire laying period. This conclusion on efficacy for 22 
laying hens can be extended to all avian species for laying when the additive is used at the same 23 
minimum dose. 24 
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1. Introduction 27 
1.1. Background and Terms of Reference 28 
Regulation (EC) No 1831/20031 establishes the rules governing the Community authorisation of 29 
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any 30 
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an 31 
application in accordance with Article 7. 32 
The European Commission received a request from Calpis Co., Ltd2 for authorisation of the product 33 
Calsporin®, Bacillus subtilis DSM 15544, when used as a feed additive for laying hens and minor avian 34 
species for laying (game birds, ducks, geese, pigeons, sporting & ornamental birds) (category: 35 
zootechnical additives; functional group: gut flora stabilisers). 36 
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the application 37 
to the European Food Safety Authority (EFSA) as an application under Article 4(1) (authorisation of a 38 
feed additive or new use of a feed additive). According to Article 8 of that Regulation, EFSA, after 39 
verifying the particulars and documents submitted by the applicant, shall undertake an assessment in 40 
order to determine whether the feed additive complies with the conditions laid down in Article 5. The 41 
particulars and documents in support of the application were considered valid by EFSA as of 16 42 
February 2015. 43 
According to Article 8 of Regulation (EC) No 1831/2003, EFSA shall determine whether the feed 44 
additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on the safety 45 
for the target animals, consumer, user and the environment and the efficacy of the product 46 
Calsporin® (Bacillus subtilis DSM 15544), when used under the proposed conditions of use (see 47 
Section 3.1.3). 48 
1.2. Additional information 49 
The additive Calsporin® is a preparation containing viable spores of a single strain of Bacillus subtilis 50 
(DSM 15544). EFSA has issued several opinions on the safety and efficacy of this product when used 51 
in chickens for fattening (EFSA, 2006, 2007a), with weaned piglets (EFSA FEEDAP Panel, 2010a) and 52 
in turkeys for fattening, ducks, geese, pigeons and other game birds for meat production, ducks, 53 
geese, pigeons, game birds, ornamental and sporting birds for rearing to point of lay, turkeys reared 54 
for breeding and chickens reared for laying (EFSA FEEDAP Panel 2010b). Subsequent to these 55 
opinions the additive was authorised for use in chickens for fattening,3 weaned piglets,4 chickens 56 
reared for laying, turkeys, minor avian species and other ornamental and game birds.5 57 
The species B. subtilis is considered by EFSA to be suitable for the qualified presumption of safety 58 
(QPS) approach to establishing safety for the target species, consumers and the environment (EFSA, 59 
2007b; EFSA BIOHAZ Panel, 2013). This approach requires the identity of the active agent to be 60 
established and the absence of toxigenic potential and susceptibility to a selected range of antibiotics 61 
to be demonstrated. EFSA considered these issues in its opinion on the safety and efficacy of 62 
Calsporin® as a feed additive for weaned piglets (EFSA FEEDAP Panel, 2010a), following the 63 
provisions of the guidance applicable at the time, and concluded that the strain could be presumed 64 
safe for the target species, consumers and the environment. Subsequently, EFSA has introduced new 65 
guidance on the determination of antibiotic susceptibility (EFSA FEEDAP Panel, 2012) and assessing 66 
                                                          
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in 
animal nutrition. OJ L 268, 18.10.2003, p. 29. 
2 Calpis Co. Ltd, represented in the EU by Calpis Co. Ltd Europe Representative Office, 46 rue Paul Valery, 75516 Paris, France. 
3 Commission Regulation (EC) No 1444/2006 of 29 September 2006 concerning the authorisation of Bacillus subtilis C-3102 
(Calsporin) as a feed additive. OJ L 271, 30.9.2006, p. 19 plus amendments. 
4 Commission Regulation (EU) No 333/2010 of 22 April 2010 concerning the authorisation of a new use of Bacillus subtilis C-
3102 (DSM 15544) as a feed additive for weaned piglets (holder of authorisation Calpis Co. Ltd. Japan, represented in the 
European Union by Calpis Co. Ltd. Europe Representative Office). OJ L 102, 23.4.2010, p. 19 
5 Commission Regulation (EU) No 184/2011 of 25 February 2011 concerning the authorisation of Bacillus subtilis C-3102 (DSM 
15544) as a feed additive for chickens reared for laying, turkeys, minor avian species and other ornamental and game birds 
(holder of authorisation Calpis Co. Ltd Japan, represented by Calpis Co. Ltd Europe Representative Office). OJ L 53, 
26.2.2011, p. 33. 
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the toxigenic potential of Bacillus species (EFSA FEEDAP Panel, 2014). Consequently, these elements 67 
of the previous assessment are reconsidered in this opinion. 68 
The use of the additive with laying hens and minor avian species for laying is considered unlikely to 69 
introduce hazards for users of the product not already considered as part of the first assessment 70 
(EFSA, 2006). Consequently, in the present opinion the FEEDAP Panel has focused only on the 71 
verification of the compliance of the active agent with the qualifications currently applied using the 72 
QPS approach and the data specific to the use of the additive in the new target species. 73 
2. Data and methodologies 74 
2.1. Data 75 
The present assessment is based on data submitted by the applicant in the form of a technical 76 
dossier6 in support of the authorisation request for the use of Calsporin® as a feed additive. The 77 
technical dossier was prepared following the provisions of Article 7 of Regulation (EC) No 1831/2003 78 
and the applicable EFSA guidance documents. 79 
The EURL considered that the conclusions and recommendations reached in the previous assessment 80 
are valid and applicable for the current application.7 81 
2.2. Methodologies 82 
The approach followed by the FEEDAP Panel to assess the safety and the efficacy of Calsporin® is in 83 
line with the principles laid down in Regulation (EC) No 429/20088 and the relevant guidance 84 
documents: Guidance on zootechnical additives (EFSA, 2012); Technical guidance on tolerance and 85 
efficacy studies in target animals (EFSA FEEDAP Panel, 2011); Guidance on the assessment of the 86 
toxigenic potential of Bacillus species used in animal nutrition (EFSA FEEDAP Panel, 2014); Technical 87 
guidance on the extrapolation of data from major species to minor species regarding the assessment 88 
of additives for use in animal nutrition (EFSA, 2008, revised in 2009); and Technical guidance on the 89 
update of the criteria used in the assessment of bacterial resistance to antibiotics of human or 90 
veterinary importance (EFSA, 2008, revised in 2012). 91 
3. Assessment 92 
Calsporin® is a preparation of viable spores of a single strain of Bacillus subtilis intended for use as a 93 
zootechical additive (gut flora stabiliser) in feed for laying hens and all avian species for laying (ducks, 94 
geese, pigeons) and for game, sporting and ornamental birds for laying. 95 
3.1. Characterisation 96 
3.1.1. Characterisation of the active agent 97 
The active agent in the additive consists of viable endospores of a single strain of B. subtilis originally 98 
isolated from soil in Japan and deposited in the German Collection of Microorganisms and Cell Cultures 99 
(DSMZ) with the accession number DSM 15544.9 100 
The battery of antibiotics currently recommended for the testing of antibiotic resistance among 101 
species of Bacillus were all included in the recommended list applicable at the time of the 2008 102 
submission for the use of the additive in piglets.10 The results presented in this application are still 103 
valid and, as the cut-off values remain the same, the conclusion on the susceptibility of the strain to 104 
all tested antibiotics is unchanged. 105 
                                                          
6  FEED dossier reference: FAD-2014-0042. 
7 The full report is available on the EURL website: https://ec.europa.eu/jrc/sites/default/files/FinRep-FAD-2009-0013.pdf 
8 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC) No 
1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications and 
the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1. 
9 Technical dossier/Section II/Annex II.2.1.2.1. 
10 Technical dossier/Section II/Annexes II.2.2.2.4 and II.2.2.2.5. 
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The technical guidance on the assessment of the toxigenic potential of Bacillus species introduced in 106 
2014 contains a substantial revision applicable to B. subtilis. The emphasis of the assessment changed 107 
from the detection of B. cereus-like toxins in the former guidance to the detection of cyclic 108 
lipopeptides able to cause measurable cell cytotoxicity. It recommends the use of a single cytotoxicity 109 
assay preferably done with Vero cells and using an established method, such as inhibition of radio- 110 
labelled leucine uptake, as evidence of toxicity. The data set generated in 2003 and used for 111 
subsequent applications included an assay with Vero cells done with a 10-fold concentrated culture 112 
supernatant of the Calsporin® strain.11 The presence of the concentrated supernatant did not inhibit 113 
leucine uptake, unlike the supernatant from the positive control, which fully inhibited uptake. 114 
Consequently, these data are considered to fulfil the requirements of the present guidance confirming 115 
the absence of toxigenic potential. 116 
3.1.2. Characterisation of the additive 117 
The additive that is the subject of the present application has the same formulation and method of 118 
manufacture as that considered in previous applications. Thus, the data pertaining to impurities and 119 
physical properties still apply. Since the first application, the applicant has continued to monitor the 120 
shelf life of the product and now has evidence, based on three batches, that losses are virtually non- 121 
existent after 10 years’ storage in commercial packaging under conditions designed to mimic ambient 122 
(25 ºC/60 % relative humidity).12 Although no specific data on stability in feed for laying hens or 123 
mixing in such feed were provided, the data on mixing and stability in premixes, mash and pelleted 124 
feeds variously produced for chickens for fattening, turkeys and piglets are considered sufficient given 125 
the similarity in feed formulation. 126 
3.1.3. Conditions of use 127 
The product is intended for use in feed for laying hens and all avian species for laying (ducks, geese, 128 
pigeons) and for game, sporting and ornamental birds for laying at a minimum dose of 3 × 108 129 
colony-forming units (CFU)/kg complete feedingstuff. 130 
3.2. Safety 131 
No evidence of toxigenic potential or resistance to antibiotics of human and veterinary importance was 132 
found, as judged by the current requirements. Thus, the conclusion reached in the previous opinion 133 
on weaned piglets (EFSA FEEDAP Panel, 2010a) that the strain B. subtilis DSM 15544 is presumed 134 
safe for target animals, consumers and the environment, is still considered to apply. This conclusion 135 
automatically covers the use of the additive in feed for laying hens and all avian species for laying. 136 
The use of the additive in laying hens and all avian species for laying is considered unlikely to 137 
introduce hazards for users of the product not already considered as part of the first assessment 138 
(EFSA, 2006). 139 
3.3. Efficacy 140 
3.3.1. Efficacy for laying hens 141 
Three trials conducted in two Member States are described. In each case trials were of 168 days’ 142 
duration and consisted of a comparison of a control group of layers with a group given the additive at 143 
the minimum recommended dose of 3 × 108 CFU/kg feed (confirmed by analysis). Birds were fed 144 
mash diets based on wheat/soybean (trial 113) or wheat/maize/soybean (trials 214 and 315), and the 145 
breeds used were Hy-Line layers (trial 1) and Tetra SL (trials 2 and 3). The total numbers of layers 146 
used and number of replicates per treatment for each trial are shown in Table 1. In trial 1, birds were 147 
purchased at 36 weeks of age and randomly allocated to cages. They were allowed four weeks 148 
                                                          
11 Technical dossier/Section II/Annex II.2.2.2.1. 
12 Technical dossier/Section II/Annex II.4.1.2. 
13 Technical dossier/Section IV and Supplementary information June 2015/Annex IV.3.1 and Addendum. 
14 Technical dossier/Section IV/Annex IV.3.2. 
15 Technical dossier/Section IV/Annex IV.3.3. 
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acclimatisation, during which time they were fed the control feed, with the start of the trial at 40 149 
weeks of age. In trials 2 and 3, observations were made from the start of laying at 19 weeks of age. 150 
Hen performance, egg production, feed consumption and feed conversion ratio were measured or 151 
calculated in all trials. Trials 2 and 3 also included the egg quality parameters (e.g. egg length, egg 152 
width, shell breaking strength, shell thickness, shell weight, shell density, shell colour, yolk weight, 153 
yolk colour, albumen height, egg cholesterol content). A more limited assessment of egg quality was 154 
made in trial 1 (cracked/dirty eggs, shell thickness and yolk colour). Faecal numbers of Clostridium 155 
perfringens and Campylobacter spp. were also monitored in trial 1. 156 
Overall production data were analysed as a randomised two-factorial design by analysis of variance. 157 
The model included the block as fixed effect and the dietary treatment and period as main effects. In 158 
trial 1, numbers of faecal microorganisms were analysed by Student’s t-test for Campylobacter spp. 159 
and Fisher’s exact test for detection rates of C. perfringens. The overall performance results for the 160 
three trials are summarised in Table 1. 161 
Table 1:  Summary of the overall performance results of the three trials made with laying hens 162 
Trial 
no 
Total number of 
animals 
Treatment 
(CFU/kg 
feed) 
Laying 
rate 
(%) 
Average 
egg 
weight 
(g) 
Daily egg 
mass 
(g/cage) 
Feed 
intake 
(g/bird) 
Egg to 
feed 
ratio No of replicates per 
treatment × no of 
birds per replicate 
1 384 0 90.3 64.3 232.8 123.1 0.47 
48 × 4 3 × 108 91.2 64.3 234.8* 122.4 0.48* 
2 120 0 91.0 60.9 110.8 122.5 0.50 
30 × 2 3 × 108 90.9 62.0* 112.7 121.9 0.51* 
3 120 0 89.6 60.8 109.0 123.9 0.49 
30 × 2 3 × 108 91.5 61.3 112.1 123.6 0.50* 
*Significantly different from the control value at at least P < 0.05. 163 
No hens died or were culled in any of the three trials and no health problems were recorded. Daily 164 
egg mass increased with treatment in all three trials but reached significance in only one. This 165 
increase was accompanied in all trials by a non-significant reduction in feed intake in the Calsporin® 166 
group compared with the control group, leading to a significant improvement in egg to feed ratio. The 167 
Panel notes that the first study was done with hens in the second half of production, whereas the 168 
second and third studies were done at the start of laying. Although hens used in the first trial were 169 
older than the age recommended in the EFSA Guidance (EFSA FEEDAP Panel, 2011), evidence was 170 
provided confirming that there was no significant difference in laying performance (average egg 171 
weight, laying intensity and number of eggs per bird) at the start of the study, which might have 172 
confounded the outcome. The positive results in this trial would appear to indicate a potential benefit 173 
of Calsporin® addition throughout laying. 174 
Inclusion of Calsporin® in diets had no significant effects on egg quality parameters, colour or 175 
cholesterol content in any of the studies, other than an effect on shell colour in trial 2. However, there 176 
was a significant shift in egg size classification in the two trials in which this was recorded, with more 177 
eggs classified as large/extra-large. This was most marked in trial 2, in which the average egg weight 178 
was significantly increased, but a similar pattern was also seen in trial 3, where the increase in egg 179 
weight did not reach significance. 180 
Analysis of faecal data after eight weeks showed a small but significant reduction in faecal 181 
Campylobacter numbers in birds fed Calsporin® compared with control birds in trial 1 (6.9 vs. 6.2 182 
log10/g faeces, P = 0.04). 183 
Conclusions on efficacy for laying hens 184 
In all three studies the amount of feed needed to produce a unit of egg mass was significantly 185 
reduced when Calsporin® was included at the minimum recommended dose of 3 × 108 CFU/kg feed. 186 
While the Panel notes that one of the studies involved layers in the second half of production, the 187 
positive outcome is taken to indicate a potential for efficacy over the entire laying period. 188 
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3.3.2. Efficacy for minor avian species for laying and for game, sporting 189 
and ornamental birds for laying 190 
The dose proposed for use in egg-laying avian species is the same as that demonstrated as effective 191 
in a physiologically similar major species (laying hens), and it can be reasonably assumed that the 192 
mode of action is the same. Consequently, the conclusion on efficacy for laying hens can be extended 193 
to all avian species for laying without the need for specific studies. 194 
3.4. Post-market monitoring 195 
The FEEDAP Panel considers that there is no need for specific requirements for a post-market 196 
monitoring plan, other than those established in the Feed Hygiene Regulation16 and Good 197 
Manufacturing Practice. 198 
4. Conclusions 199 
No evidence of toxigenic potential or resistance to antibiotics of human and veterinary importance is 200 
found, as judged by the current guidelines. The conclusion reached in previous opinions, that the 201 
strain B. subtilis DSM 15544 is presumed safe for target animals, consumers and the environment, is 202 
still considered valid. This conclusion automatically covers the use of the additive in feed for laying 203 
hens and all avian species for laying. 204 
Use of the additive in feed for laying hens and all avian species for laying will not introduce hazards 205 
for users not already considered. 206 
In all three studies the amount of feed needed to produce a unit of egg mass was significantly 207 
reduced when Calsporin® was included at the minimum recommended dose of 3 × 108 CFU/kg feed. 208 
While the Panel notes that one of the studies involved layers in the second half of production, the 209 
positive outcome is taken to indicate the potential for efficacy over the entire laying period. The 210 
conclusion on efficacy for laying hens can be extended to all avian species for laying when the 211 
additive is used at the same minimum dose. 212 
                                                          
16 Regulation (EC) No 183/2005 of the European Parliament and of the Council of 12 January 2005 laying down requirements for 
feed hygiene. OJ L 35, 8.2.2005, p. 1. 
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Documentation provided to EFSA 213 
1. Calsporin® Bacillus subtilis C-3102, DSM 15544 Zootechnical feed additive for laying hen & 214 
minor avians in lay. Functional group: gut flora stabiliser. January 2015. Submitted by Calpis 215 
Co. Ltd. 216 
2. Calsporin® Bacillus subtilis C-3102, DSM 15544 Zootechnical feed additive for laying hen & 217 
minor avians in lay. Supplementary information. June 2015. Submitted by Calpis Co. Ltd. 218 
3. Comments from Member States. 219 
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Abbreviations 260 
CFU colony-forming unit 
EURL European Union Reference Laboratory 
FEEDAP EFSA Panel on Additives and Products or Substances used in Animal Feed 
QPS qualified presumption of safety 
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